Stay updated with breaking news from Nova Mentis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global
KGK Sciences Inc. received a no objection letter from Health Canada to proceed with a phase 2a clinical trial evaluating the use of psilocybin for fragile X syndrome, the leading genetic cause of autism spectrum disorder. According to a company press release, the results of a 10-person, open-label study will be used to support KGK’s client Nova Mentis’ drug development program under
Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has received a 'No Objection letter'...
Coronavirus Treatment and Cure news - updated 24/7/365. We link to the best sources from around the world. Get the latest news…